Clinical trial
A Gene Therapy Study for Hemophilia B
NCT02484092 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT02484092 |
|---|---|
| Title | A Gene Therapy Study for Hemophilia B |
| Official title | Gene Therapy, Open-label, Dose-escalation Study of PF-06838435 (SPK-9001) [Adeno-associated Viral Vector With Human Factor IX Gene] in Subjects With Hemophilia B |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hemophilia B |
| Intervention type | Biological |
| Interventions | SPK-9001 |
| Enrollment | 15 |
| Start date | Nov 18, 2015 |
| Primary completion | Apr 8, 2019 |
| Completion | Apr 8, 2019 |
| First posted | Jun 29, 2015 |
| Last update posted | Jun 16, 2020 |
| Countries | Australia, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: